EB66 NTCC?疫苗和治療性蛋白生產用鴨胚胎干細胞株duck embryonic stem cell-BioVector NTCC質粒載體菌株細胞蛋白抗體基因保藏中心

The NTCC? EB66 cell line is a duck embryonic stem cell-derived cell line that has been developed as a platform for the production of vaccines and therapeutic proteins. It is considered a valuable tool in the biotechnology industry due to its unique characteristics and advantages.

NTCC? EB66 cell line

Key characteristics of the NTCC? EB66 cell line:

• Origin: Derived from duck embryonic stem cells

• Advantages:

  • High growth rate: Short population doubling time, allowing for rapid cell expansion.

  • High cell density: Can reach very high cell densities in culture, increasing production yields.

  • Unique metabolic profile: Low ammonium and lactate accumulation, reducing the need for frequent media changes.

  • Reduced fucose content: Leads to enhanced antibody-dependent cellular cytotoxicity (ADCC) activity of therapeutic antibodies produced in this cell line.

  • Genetic stability: Maintained through the expression of telomerase, ensuring long-term culture stability.

  • Scalability: Can be easily scaled up for industrial production in bioreactors.

  
  

Applications of the EB66 cell line:

• Vaccine production: Used for the production of a variety of human and veterinary vaccines, including influenza, rabies, and Zika virus vaccines.

• Therapeutic protein production: Used for the production of therapeutic antibodies and other recombinant proteins.

Advantages of using the EB66 cell line:

• Consistent product quality: The use of a well-characterized cell line ensures consistent product quality and reproducibility.

• Reduced production costs: The high growth rate and scalability of the EB66 cell line can lead to reduced production costs.

• Enhanced product efficacy: The reduced fucose content of antibodies produced in EB66 cells can lead to enhanced ADCC activity, improving their therapeutic efficacy.

Overall, the NTCC? EB66 cell line is a valuable tool for the production of vaccines and therapeutic proteins. Its unique characteristics and advantages make it a promising platform for the development of new and improved biopharmaceuticals.

NTCC?EB66 Cell Line Culture Techniques

EB66 cells are expanded to required pre-infection densities in BioVector? EB66Complete Medium-I (Catalog No. BioVector?-931135M1) growth medium. EB66 cellsare normally grown at 37±1^oCand 7.5% CO2 in shaker flasks at 120 rpm.

Virusinfection and production is induced with the addition of seed virus and 1.5 -1.8 times (v/v) pre-warmed BioVector? EB66 Complete Medium-II (Catalog No.BioVector?-931135MII) medium to growth medium. Standard infection celldensities are >2 x 10⁶ viable cells/mL (prior to dilution withproduction medium) at a multiplicity of infection (MOI) of 0.01 - 0.10.

Optimalconditions for virus amplification may vary depending on viral construct andprocess conditions. Recommended post-infection conditions are 33 to 37 °C and7.5 % CO2 in shaker flasks at 120 rpm.

Cryopreservation

BioVector?EB66 Complete Medium-II is not recommended for cryopreservation of the EB66cell line. Please refer to BioVector? EB66 Complete Medium-I (Catalog No.BioVector?-931135M1) growth medium literature for recommended cryopreservation conditions.

NTCC? EB66 細胞系是一種來源于鴨胚胎干細胞的細胞系，已被開發為生產疫苗和治療性蛋白的平臺。由于其獨特的特性和優勢，它被認為是生物技術行業中一種有價值的工具。

NTCC?EB66 細胞系的關鍵特征：

• 起源： 源自鴨胚胎干細胞

• 優勢：

  • 高生長速率： 細胞倍增時間短，可快速擴增細胞。

  • 高細胞密度： 在培養中可達到非常高的細胞密度，從而提高產量。

  • 獨特的代謝特征： 氨和乳酸積累較少，減少了頻繁更換培養基的需求。

  • 降低巖藻糖含量： 導致在該細胞系中產生的治療性抗體的抗體依賴性細胞毒性 (ADCC) 活性增強。

  • 遺傳穩定性： 通過端粒酶的表達維持，確保長期培養穩定性。

  • 可擴展性： 可在生物反應器中輕松放大生產。

  
  

EB66 細胞系的應用：

• 疫苗生產： 用于生產多種人類和獸用疫苗，包括流感、狂犬病和寨卡病毒疫苗。

• 治療性蛋白生產： 用于生產治療性抗體和其他重組蛋白。

使用 EB66 細胞系的優勢：

• 一致的產品質量： 使用經過充分表征的細胞系可確保一致的產品質量和可重復性。

• 降低生產成本： EB66 細胞系的高生長速率和可擴展性可降低生產成本。

• 提高產品功效： 在 EB66 細胞中產生的抗體巖藻糖含量降低可提高 ADCC 活性，從而提高其治療功效。

總的來說，NTCC? EB66 細胞系是生產疫苗和治療性蛋白的有價值工具。其獨特的特性和優勢使其成為開發新型和改進型生物制藥產品的有前途的平臺。

生產廠家Supplier:

BioVector NTCC質粒載體菌株細胞蛋白抗體基因保藏中心

E-mail:BioVector@163.com

http://www.biovector.net